[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimers-diseasead\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimers-diseasead":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,55,85,112,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100609370","inrad-observational-study-100609370",false,"NCT07213700","InRAD Observational Study","The International Registry for Alzheimer's Disease and Other Dementias (InRAD): An International Registry Observational Study Dedicated to Evaluating Outcomes Data in Alzheimer's Disease","InRAD","Inclusion Criteria:\n\n* Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR\n* Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated),\n* Be attending an InRAD Center,\n* Have provided informed consent for long-term follow-up\n\nExclusion Criteria:\n\n-Any patient or legal representative who is unable or unwilling to provide a signed informed consent form","ALL",{"count":19,"type":20},50000,"ESTIMATED","10 Years","OBSERVATIONAL","The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers.\n\nThe InRAD Registry Observational Study has several aims:\n\n* To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease.\n* To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease.\n* To enable researchers to answer similar research questions and compare results in many different areas of the world.\n\nPeople with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.",[25,26,27,28],"Alzheimer's Disease(AD)","Mild Cognitive Impairment (MCI)","Subjective Cognitive Decline (SCD)","Non-Alzheimer Degenerative Dementia",[30,31,32,33,34,35,36,37,38,39,40,41],"Alzheimer's disease (AD)","Dementia","Observational study","Real-world data (RWD)","International registry","Cognitive decline","Lecanemab","InRAD Registry","InRAD Foundation","Cognitive screening (MoCA, MMSE)","AD-specific therapies","Clinical staging","RECRUITING","2026-07-01",{"date":45,"type":46},"2026-07-02","ACTUAL",{"date":48,"type":46},"2026-03-30",{"date":50,"type":20},"2036-01",{"name":52,"class":53},"Stichting International Registry for Alzheimer's Disease and other Dementias Foundation","OTHER",6,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":17,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":84},"100636825","community-based-screening-for-alzheimers-disease-100636825","NCT07570719","Community-based Screening for Alzheimer's Disease","Stratified Screening of Blood Biomarkers for Alzheimer's Disease: a Prospective, Real World, Community-based Study","CSAD","Inclusion Criteria:\n\n* Aged 60-80 years\n* Capable of normal communication and able to complete the questionnaire\n\nExclusion Criteria:\n\n* Severe mental disorders\n* Severe visual, auditory, comprehension or mobility impairments\n* Current participation in other health intervention clinical studies\n* Severe renal insufficiency, heart failure, cerebrovascular disease, anemia, hyperthyroidism, hypothyroidism\n* Multiple cerebral infarctions, severe white matter hyperintensities, history of cerebral hemorrhage, current anticoagulant use, MRI abnormalities (cortical iron deposition, cerebral contusion)\n* Unable to comply with study procedures with no legal guardian",true,"60 Years","80 Years",{"count":67,"type":20},3000,"The goal of this prospective, multicenter, observational cohort study is to evaluate the screening performance of blood-based biomarkers for Alzheimer's disease (AD) in a real-world community screening setting, and to establish the population baseline levels and reference intervals of these biomarkers in Chinese older adults.\n\nThe main questions it aims to answer is:\n\nWhat is the clinical screening value of blood biomarkers (phosphorylated tau 217 to amyloid β 42 ratio \\[pTau217\u002FAβ42\\] and glial fibrillary acidic protein \\[GFAP\\]) for AD among community-dwelling older adults? Eligible study participants will be randomly enrolled from community-dwelling older adults undergoing routine physical examinations and outpatient clinic attendees. All enrolled participants will undergo AD screening via blood biomarker testing. Participants with positive blood biomarker results (defined as abnormal pTau217\u002FAβ42 ratio and\u002For GFAP levels) will further complete a full battery of cognitive scale assessments, including the Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Activities of Daily Living (ADL) scale, and 17-item Hamilton Depression Rating Scale (HAMD-17). In addition, 15% of participants with negative blood biomarker results, selected via random sampling, will also complete the same cognitive scale assessments.",[25,26,70],"Cognitive Impairment",[72,70,73,74],"Alzheimer's disease","Screening","Blood biomarker","2026-04-29",{"date":77,"type":46},"2026-05-06",{"date":79,"type":20},"2026-05-01",{"date":81,"type":20},"2028-03-31",{"name":83,"class":53},"Kuang XiaoJun",4,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":63,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":97,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":101,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100630586","phase-1-a-study-of-qlh2405-in-healthy-participants-and-participants-with-mild-cognitive-impairment-due-to-alzheimers-disease-and-mild-alzheimers-disease-100630586","NCT07489599","A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Subcutaneous, Ascending Doses of QLH2405 Injection in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","Inclusion Criteria for Part A:\n\n1. Voluntarily participate and sign the informed consent.\n2. Male or female, aged 18 to 65 years (inclusive).\n3. Healthy status as confirmed by medical evaluation.\n4. Body mass index (BMI) of 19-28 kg\u002Fm² (inclusive).\n5. Agree to use effective contraception and have no plans for sperm\u002Fegg donation or pregnancy from ICF signing until 9 months post-dose.\n\nInclusion Criteria for Part B:\n\n1. Voluntarily participate and sign the informed consent, able to communicate well with the investigator and complete the trial per protocol.\n2. Male or female, aged 50 to 85 years (inclusive).\n3. A diagnosis of mild MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.\n4. Has subjective cognitive and memory decline for ≥6 months.\n5. Confirmation of Alzheimer's disease pathological changes by amyloid PET (Aβ-PET) scan.\n6. Has one (or more) reliable study partner (s)\u002Fadult caregiver(s) can accompany the participant to all visits.\n7. Agree to use effective contraception and have no plans for sperm\u002Fegg donation or pregnancy from ICF signing until 9 months post-dose.\n\nExclusion Criteria for Part A:\n\n1. History of significant diseases, or any existing disease may affect the study or pose an unacceptable risk to the participant.\n2. Positive for HBsAg, HIV-Ab, Treponema pallidum antibody, or HCV-Ab.\n3. History of blood donation, significant blood loss (total volume ≥400 mL), or blood transfusion within 3 months prior to screening.\n4. History of alcohol abuse within 1 year prior to screening; or positive alcohol breath test.\n5. History of drug abuse and\u002For substance abuse; or positive drug screening.\n6. Participation in any drug or medical device clinical trial within 3 months prior to screening.\n7. Pregnant or lactating women, or women of childbearing potential with a positiveβ-hCG test.\n8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.\n\nExclusion Criteria for Part B:\n\n1. Cognitive impairment or dementia caused by any disease other than AD.\n2. History of stroke within 6 months prior to screening, or imaging evidence of clinically significant central nervous system diseases.\n3. History of epileptic seizures or epileptiform abnormalities on EEG within 6 months prior to screening.\n4. Unstable or severe diseases within 6 months prior to screening that, in the investigator's judgment, make the participant unsuitable for study participation.\n5. eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m².\n6. AST or ALT \\>3 × upper limit of normal (ULN), or total bilirubin \\>2 × ULN.\n7. Current use or anticipated need during the study period for any medication prohibited by the study protocol.\n8. Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.","18 Years","85 Years",{"count":95,"type":20},68,"INTERVENTIONAL",[98],"PHASE1","The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.",[25,26],"NOT_YET_RECRUITING","2026-03-18",{"date":104,"type":46},"2026-03-24",{"date":106,"type":20},"2026-03",{"date":108,"type":20},"2027-03",{"name":110,"class":111},"Qilu Pharmaceutical Co., Ltd.","INDUSTRY",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":63,"sex":17,"minAge":92,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100417416","upenn-observational-research-repository-on-neurodegenerative-disease-100417416","NCT04715399","UPenn Observational Research Repository on Neurodegenerative Disease","University of Pennsylvania Centralized Observational Research Repository on Neurodegenerative Disease (UNICORN)","UNICORN","Inclusion Criteria:\n\nThis protocol will include 3 groups of people:\n\n1. People with a clinical diagnosis of a neurodegenerative disease. such as frontotemporal degeneration(FTD), primary progressive aphasia(PPA), Lewy body disease(LBD), amyotrophic lateral sclerosis(ALS), progressive supranuclear palsy(PSP), corticobasal syndrome(CBS), posterior cortical atrophy(PCA), Alzheimer's disease(AD), Parkinson's disease(PD)\n2. People with a family history of neurodegenerative disease who may or may not be symptomatic, and may or may not be mutation carriers such as familial frontotemporal lobar degeneration (fFTLD) or familial ALS,\n3. People with no known neurological disease who will provide control data.\n\nExclusion Criteria:\n\n* Anyone who is under the age of 18.\n* Anyone with a condition or in a situation which, in the Investigator's opinion, could confound the study findings or may interfere significantly with a person's participation, including but not limited to neurological, psychological and other medical conditions (such as cardiac, neurosurgical, infectious conditions).\n* Individual participants may be excluded from some, but not all, study procedures for safety reasons when they have a contraindication or at the discretion of the Investigator. For example, persons with metal implants which are not MRI-safe will not be able to take part in imaging, and those on blood thinning medications may not be able to take part in lumbar puncture.\n* Pregnant women; if a woman becomes pregnant during the study, research activities that may increase risk to the patient and the unborn fetus will be stopped until the end of pregnancy, at which point participation can be resumed.",{"count":121,"type":20},1000,"The aim of this study is to create a repository of both cross-sectional and longitudinal data, including cognitive, linguistic, imaging and biofluid biological specimens, for neurodegenerative disease research and treatment.",[124,125,126,127,128,129,130,131,25],"Frontotemporal Degeneration(FTD)","Primary Progressive Aphasia(PPA)","Familial Frontotemporal Lobar Degeneration (fFTLD)","Amyotrophic Lateral Sclerosis(ALS)","Lewy Body Disease(LBD)","Progressive Supranuclear Palsy(PSP)","Corticobasal Syndrome(CBS)","Posterior Cortical Atrophy(PCA)","2026-01-21",{"date":134,"type":46},"2026-01-22",{"date":136,"type":46},"2020-05-29",{"date":138,"type":20},"2070-05-30",{"name":140,"class":53},"University of Pennsylvania",1,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":149,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":96,"phases":153,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100611340","neuclare-device-for-temporary-improvement-of-executive-function-in-patients-with-mild-cognitive-impairment-and-prodromal-alzheimers-disease-100611340","NCT07239310","Neuclare Device for Temporary Improvement of Executive Function in Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease","A Prospective, Multicenter, Randomized, Double-Blind, Parallel-Group, Confirmatory Clinical Trial to Verify the Efficacy and Safety of the Cognitive Improvement Effect on Executive Function in Medication-Treated Patients With Mild Cognitive Impairment and Prodromal Alzheimer's Disease Using the Neuclare Physical Device for Medical Use","Inclusion Criteria:\n\n1. Adults aged 55 to 90 years.\n2. Diagnosed with probable Alzheimer's disease according to NINCDS-ADRDA criteria and DSM-IV criteria for dementia,\n3. or mild cognitive impairment\u002Fvery mild Alzheimer's disease with CDR 0.5-1 and MMSE-II ≥18.\n4. On stable cognitive therapy medications for at least 1 month.\n5. Voluntary participation with signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with structural brain lesions detected on brain MRI (e.g., cerebral edema, intracerebral hemorrhage, cerebral infarction, cerebrovascular malformation, brain tumor, etc.).\n2. Patients with uncontrolled metabolic disorders such as thyroid dysfunction, hypoglycemia, or hepatic\u002Frenal impairment, or those on long-term medications that may cause cognitive impairment (e.g., anticholinergic drugs).\n3. Patients with a history of epileptic seizures, depression, or psychiatric disorders; patients experiencing visual hallucinations or fluctuating cognitive decline.\n4. Patients with psychiatric disorders outside of the inclusion criteria.\n5. Patients with a history of severe diseases such as cancer or tuberculosis.\n6. Patients with a history of or currently taking psychoactive drugs or medications affecting the central or peripheral nervous system.\n7. Patients with contact dermatitis or other skin hypersensitivity conditions.\n8. Patients with fever ≥ 40°C as measured by tympanic temperature.\n9. Patients who have experienced bleeding within the past 3 months due to procedures or surgeries that may affect vital signs.\n10. Patients unable to undergo MRI.\n11. Pregnant patients.\n12. Patients with clinical brain calcification observed on computed tomography (CT) scans.\n13. Patients with known allergies to contrast agents such as Definity or Gadovist.\n14. Any other condition deemed by the investigator to make participation in the clinical trial inappropriate.","55 Years","90 Years",{"count":152,"type":20},138,[154],"NA","This study is a multicenter, randomized, double-blind, parallel-group, prospective confirmatory clinical trial designed to evaluate whether the Neuclare medical device can temporarily improve executive function (planning and problem-solving abilities) in adults with mild cognitive impairment or very early Alzheimer's disease.\n\nParticipants will continue their current medication and be randomly assigned to receive either the Neuclare device (treatment group) or a sham device (control group). The device will be applied to the brain three times per week for four weeks. Both participants and study staff are blinded to the group assignment. Safety and adverse events will be closely monitored throughout the study.\n\nDuring the trial, assessments will include attention, cognitive function, daily living activities, brain imaging (Amyloid PET-CT), blood biomarkers, and quality of life (EQ-5D-5L).\n\nThe goal of this study is to determine whether the Neuclare device, in combination with standard medication, can safely provide temporary improvements in executive function.",[157,25],"Mild Cognitive Impairment","2025-12-08",{"date":160,"type":46},"2025-12-10",{"date":162,"type":46},"2025-11-20",{"date":164,"type":20},"2026-07",{"name":166,"class":111},"Deepsonbio",3]